Minute Insight: Venus Buys Transcatheter Valve Developer Cardiovalve For $300M
Israel-based Cardiovalve is developing a transcatheter valve replacement system to treat mitral and tricuspid valve regurgitation.
You may also be interested in...
Venus Medtech has agreed a licensing deal with Endoluminal Sciences, an Australian start-up with technology to prevent paravalvular leakage and improve TAVR outcomes.
Harpoon is a minimally invasive surgery device that complements Edwards pipeline of transcatheter mitral and septal valve repair and replacement technologies, which now includes at least six technologies at various stages of development, and is one of the company's top R&D priorities.
Navitor is an upgraded version of Abbott’s Portico TAVR system with a better fabric cuff and large curved aortic “cells” to reduce the risk of injury to the native valve.